- |||||||||| tibulizumab (ZB-106) / Zura Bio
Enrollment closed: A Study of LY3090106 in Participants With Sj (clinicaltrials.gov) - Feb 20, 2018 P1, N=32, Active, not recruiting, Recruiting --> Active, not recruiting | N=60 --> 23 Recruiting --> Active, not recruiting
- |||||||||| Trial completion, Trial completion date: SINAPPS-1: Study of Immunotherapy in Autoantibody Positive Psychosis (clinicaltrials.gov) - Feb 19, 2018
P=N/A, N=10, Completed, Recruiting --> Completed | N=20 --> 10 | Trial primary completion date: Dec 2015 --> May 2017 Recruiting --> Completed | Trial completion date: Oct 2017 --> Dec 2017
- |||||||||| Trial completion: Pre-POINT-Early Study (clinicaltrials.gov) - Feb 13, 2018
P2, N=44, Completed, Active, not recruiting --> Completed | Trial completion date: Jan 2018 --> Feb 2018 | Trial primary completion date: Jan 2018 --> Feb 2018 Active, not recruiting --> Completed
- |||||||||| Trial completion, Trial completion date, Trial primary completion date: Open-label Study of Liothyronine in MS (clinicaltrials.gov) - Feb 12, 2018
P1b, N=20, Completed, Recruiting --> Completed | Trial completion date: Mar 2018 --> Nov 2017 | Trial primary completion date: Sep 2017 --> Nov 2017 Active, not recruiting --> Completed | Trial completion date: Aug 2017 --> Sep 2017 | Trial primary completion date: Aug 2017 --> Sep 2017
- |||||||||| Catena (idebenone) / Chiesi
Trial primary completion date: Clinical Trial of Idebenone in Primary Progressive Multiple Sclerosis (IPPoMS) (clinicaltrials.gov) - Feb 9, 2018 P1/2, N=85, Active, not recruiting, Active, not recruiting --> Completed | Trial completion date: Aug 2017 --> Sep 2017 | Trial primary completion date: Aug 2017 --> Sep 2017 Trial primary completion date: Aug 2018 --> Apr 2018
- |||||||||| Trial completion date, Trial primary completion date: The Clinical Efficacy of DFPP in Patients With AAGN (clinicaltrials.gov) - Feb 6, 2018
P=N/A, N=14, Terminated, Enrolling by invitation --> Completed | Trial primary completion date: Jun 2017 --> Feb 2017 Trial primary completion date: Nov 2017 --> Apr 2017 | Trial completion date: Nov 2018 --> Apr 2017
- |||||||||| Trial completion, Phase classification, Enrollment change, Trial primary completion date: Psychosocial Issues in Insulin Pump Therapy in Children With Type 1 Diabetes Mellitus (DM) (clinicaltrials.gov) - Feb 5, 2018
P=N/A, N=211, Completed, Trial primary completion date: Nov 2017 --> Apr 2017 | Trial completion date: Nov 2018 --> Apr 2017 Recruiting --> Completed | Phase classification: P4 --> PN/A | N=272 --> 211 | Trial primary completion date: Jun 2013 --> Jul 2015
- |||||||||| daxdilimab (HZN-7734) / Horizon Therapeutics
Trial completion, Trial completion date: A Phase 1 Study of MEDI7734 in Type I Interferon-Mediated Autoimmune Diseases (clinicaltrials.gov) - Feb 5, 2018 P1, N=36, Completed, Recruiting --> Completed | Phase classification: P4 --> PN/A | N=272 --> 211 | Trial primary completion date: Jun 2013 --> Jul 2015 Active, not recruiting --> Completed | Trial completion date: Jul 2018 --> Nov 2017
- |||||||||| Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche
Trial termination, Trial primary completion date: RITUXILUP: Trial of Rituximab and Mycophenolate Mofetil Without Oral Steroids for Lupus Nephritis (clinicaltrials.gov) - Feb 1, 2018 P3, N=24, Terminated, Suspended --> Terminated | Trial primary completion date: Sep 2017 --> Dec 2017; Study assessments for patients recruited continuing per protocol so patients receive a minimum of 6 months follow up. No safety concerns have been raised.
- |||||||||| Actemra SC (tocilizumab SC) / Roche, Halozyme
Trial completion, Trial primary completion date, HEOR: An Observational Study to Evaluate the Clinical Effectiveness, Quality of Life, Safety and Tolerability of Tocilizumab (TCZ) in Patients With Rheumatoid Arthritis (RA) in Daily Clinical Practice (clinicaltrials.gov) - Jan 31, 2018 P=N/A, N=140, Completed, Recruiting --> Active, not recruiting Active, not recruiting --> Completed | Trial primary completion date: Oct 2018 --> Oct 2017
- |||||||||| thyroxine / Generic mfg.
Trial completion, Phase classification, Enrollment change, Trial primary completion date: Selenium Supplementation in Pregnancy (clinicaltrials.gov) - Jan 30, 2018 P=N/A, N=56, Completed, N=45 --> 0 | Not yet recruiting --> Withdrawn Recruiting --> Completed | Phase classification: P4 --> PN/A | N=150 --> 56 | Trial primary completion date: May 2015 --> Jun 2017
- |||||||||| rivaroxaban / Generic mfg., warfarin / Generic mfg.
Enrollment change, Trial termination, Trial primary completion date: TRAPS: Rivaroxaban in Thrombotic Antiphospholipid Syndrome (clinicaltrials.gov) - Jan 30, 2018 P3, N=121, Terminated, Recruiting --> Completed | Phase classification: P4 --> PN/A | N=150 --> 56 | Trial primary completion date: May 2015 --> Jun 2017 N=536 --> 121 | Recruiting --> Terminated | Trial primary completion date: Dec 2020 --> Jan 2018; Unbalance in the composite endpoint between arms.
- |||||||||| Ninlaro (ixazomib) / Takeda
Enrollment change, Trial termination, Trial primary completion date: Safety, Tolerability and Pharmacokinetics of Multiple Rising Doses of Ixazomib in Lupus Nephritis (LN) (clinicaltrials.gov) - Jan 29, 2018 P1b, N=12, Terminated, N=536 --> 121 | Recruiting --> Terminated | Trial primary completion date: Dec 2020 --> Jan 2018; Unbalance in the composite endpoint between arms. N=40 --> 12 | Recruiting --> Terminated | Trial primary completion date: Jun 2018 --> Jan 2018; Insufficient enrollment, no safety or efficacy concerns
- |||||||||| Enrollment closed, Trial primary completion date: Psychosocial Functioning in Young Adults With Type 1 Diabetes (clinicaltrials.gov) - Jan 29, 2018
P=N/A, N=120, Active, not recruiting, Trial primary completion date: Sep 2017 --> Sep 2019 Enrolling by invitation --> Active, not recruiting | Trial primary completion date: Dec 2017 --> Sep 2018
- |||||||||| Trial initiation date: Tissue Sodium in Autoimmune Disease (clinicaltrials.gov) - Jan 25, 2018
P=N/A, N=21, Not yet recruiting, Recruiting --> Completed | N=158 --> 124 Initiation date: Dec 2017 --> Dec 2018
- |||||||||| Sylvant (siltuximab) / Jazz
Trial completion: Modulation of STAT3 Signaling With Siltuximab in Type 1 Diabetes (clinicaltrials.gov) - Jan 18, 2018 P1, N=10, Completed, Active, not recruiting --> Completed | N=15 --> 19 | Trial primary completion date: Jan 2018 --> Mar 2017 Active, not recruiting --> Completed
- |||||||||| gerilimzumab (ARGX-109) / argenx
Trial initiation date, Trial primary completion date: Study Evaluating Gerilimzumab (clinicaltrials.gov) - Jan 18, 2018 P2, N=200, Not yet recruiting, Trial primary completion date: Dec 2017 --> Dec 2018 Initiation date: Nov 2016 --> Jan 2018 | Trial primary completion date: May 2018 --> May 2019
|